TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00354120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alentuzumab
Description: Alentuzumab
Study: NCT04180696

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aCRT OFF
Description: CRT device with AdaptivCRT disabled
Study: NCT00842348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: Autogel 120 mg
Study: NCT03942978

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal Equity Action Plan
Description: Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
Study: NCT00354120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Globulina antilinfocitaria
Description: Globulina antilinfocitaria
Study: NCT03029052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reconciliation
Description: In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
Study: NCT02607904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT03326323

Intervention type: PROCEDURE
Intervention: Acute Normovolemic Hemodilution
Description: Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
Study: NCT03081494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spartalizumab (PDR001)
Description: 100 mg lyophilisate in vial received 400 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
Study: NCT00779506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate XR
Description: oral, once daily, flexible dose
Study: NCT03563807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Golf Instruction
Description: Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi Class
Description: Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
Study: NCT02944604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study: NCT02809872

Intervention type: OTHER
Intervention: Diagnostic Thoracic Ultrasound
Study: NCT02094001

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)
Description: After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
Study: NCT04336891

Intervention type: DRUG
Intervention: Testosterone gel
Description: Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months

Intervention type: DRUG
Intervention: Estradiol ovules
Description: Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months

Intervention type: DRUG
Intervention: Moisturizer
Description: Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed

Intervention type: DRUG
Intervention: Testosterone gel + Estradiol ovules
Description: Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
Study: NCT04325490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid powder
Description: apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
Study: NCT01858766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01876069

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge ProCore needle aspiration
Description: Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge Fine needle aspiration
Description: Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
Study: NCT00457938

Intervention type: OTHER
Group type: OTHER
Intervention: low-fat diet ( Still recruiting )
Description: This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: 10 % versus 35 % fat in diet
Study: NCT03517709

Intervention type: OTHER
Group type: OTHER
Intervention: Primary Care Physician Management of blood pressure
Description: * You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~* Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. .

Intervention type: DEVICE
Group type: OTHER
Intervention: Withings Smart Blood Pressure Monitor
Description: We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
Study: NCT03946397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulstisensory massage
Description: 7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
Study: NCT01462357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: 2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: 2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
Study: NCT04325490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone cream 1%
Description: apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
Study: NCT02649673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated GCSF (PEG-GCSF)
Description: Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
Study: NCT04143815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01 (Botulinum toxin A)
Description: Intramuscular injection, dose varies by groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01 (Botulinum toxin A)
Description: Intramuscular injection, dose varies by groups
Study: NCT01462357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: 2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
Study: NCT03265340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dTMS
Study: NCT04143815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01 (Botulinum toxin A)
Description: Intramuscular injection, dose varies by groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT01363232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + MEK162
Study: NCT04019028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low frequency rTMS + Navigation System
Description: 1Hz low-frequency rTMS stimulation over primary motor area using navigation system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: only low frequency rTMS
Description: 1Hz low-frequency rTMS stimulation over primary motor area

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low frequency rTMS + Navigation System
Description: 1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
Study: NCT03937882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
Study: NCT03373916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Description: The peer mentor will meet with the participant for the first time while the participant is still in the hospital. Sessions will be scheduled according to the participant's preferences, with a suggested maximum frequency of twice weekly for the first two weeks, weekly for weeks 3 to 8, and then every other week for the last month. Allowable meeting locations include public places in the community (e.g., coffee shop, park), the participant's home, or a research clinic space or by phone. Session content is flexible and allows for the peer mentor to provide general supportive listening, validation, and sharing. Session duration is on average 1 hour with at least 15 minutes discussing hope or belongingness according to semi-structured conversation guides. The session structure and content are intentionally highly flexible to allow for genuineness in the peer relationship, thereby increasing acceptability and implicit belongingness.
Study: NCT03265340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dTMS
Study: NCT03331757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT03373916

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts.
Study: NCT02569398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atabecestat, 5 mg
Description: One atabecestat, 5 mg tablet orally once daily up to 54 months.
Study: NCT03331757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fir honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fir honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fir honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT02569398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atabecestat, 25 mg
Description: One atabecestat, 25 mg tablet orally once daily up to 54 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo tablet orally once daily up to 54 months.
Study: NCT00451776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: patients who received etomidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: patients who received propofol
Study: NCT03331757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT02326909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
Study: NCT03331757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT01840332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-thyroxin
Description: Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is \< 30 after 4 weeks the study continues up to 6 weeks.
Study: NCT00987909

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Specific allergen immunotherapy (placebo)
Description: Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific allergen immunotherapy
Description: Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific allergen immunotherapy
Description: Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific allergen immunotherapy
Description: Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
Study: NCT04524663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Camostat Mesilate administered as oral tablets
Study: NCT01462357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
Study: NCT04524663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match camostat mesilate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT01195610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Instruction to diet for 6 month

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Instruction to diet for 6 month
Study: NCT04524663

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Treatment
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT00987558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study: NCT03461224

Intervention type: RADIATION
Intervention: accelerated hypofractionated RT

Intervention type: RADIATION
Intervention: conventional fractionated RT
Study: NCT01106456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All Nations Breath of Life (ANBL)
Description: ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nontailored program (NT)
Description: The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
Study: NCT01479231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole
Description: Dexlansoprazole 60 mg daily for 6 weeks
Study: NCT01461018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune globulin subcutaneous (Human)
Description: IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
Study: NCT01698749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long acting intravitreal dexamethasone implant
Description: Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
Study: NCT02025127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Enteral nutrition introduced via a feeding tube
Study: NCT00467974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEA with LEM
Description: Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transarterial chemoembolisation (TACE)
Study: NCT04138758

Intervention type: DRUG
Intervention: Tiotropium bromide + Olodaterol
Description: Tiotropium bromide + Olodaterol

Intervention type: DRUG
Intervention: LABA/ICS
Description: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Study: NCT03999203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid
Description: Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients